ESMO IO 2022 – Luca Mazzarella

Luca Mazzarella discusses the effects of modifying the pharmacology of anti-PD1 agents on their efficacy/toxicity in patients with advanced squamous NSCLC, explains potential therapeutic benefits of adding anti-CTLA4 or de-escalating chemotherapy to anti-PD1 blockade and highlights the role of individual or combined predictive biomarkers and biostatistics tools.

Here is the full ESMO IO 2022 Solid Tumors report.

More posts

Emerging therapies in solid tumors

Interleukin-8 (IL-8), also known as chemokine (C-X-C motif) ligand 8, is a pro-inflammatory chemokine that ­exerts direct pro-tumorigenic effects ­primarily by recruiting immunosuppressive cells into the tumor microenvironment such as neutrophils and myeloid-derived suppressor cells. IL-8 has also been shown to promote cancer progression and resistance to therapy, by inducing angiogenesis, epithelial-mesenchymal transition (EMT), and cancer stem cell (CSC) self-renewal.

New strategies with PD-1/PD-L1 blockade in lung cancer

Small-cell lung cancer (SCLC) accounts for about 15 % of all diagnosed cases of lung cancer and is characterized by a high proliferative rate, an early development of widespread metastases and a poor prognosis. The five-year survival rate is less than 7 %. More than two-thirds of patients with this highly aggressive neuroendocrine tumor are diagnosed with advanced or extensive-stage disease (ES-SCLC).

Preface – ESMO IO 2022

The ESMO Immuno-Oncology Congress took place in Geneva, Switzerland, and virtually from 7th to 9th December 2022. In total, more than 2,000 participants from more than 100 countries attended one of the 31 sessions featuring over 249 presented abstracts, 6 late breaking abstracts, 6 proffered paper, 14 mini orals and 229 posters.